Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.

2 Nov 2010

Non-dividing cells can also start cancer

Cancer Research UK scientists have found that non-dividing cells are able to kick-start some cancers, challenging a long held belief that only dividing cells, like stem cells, cause the disease, according to research published online in PNAS today (Monday).

2 Nov 2010

‘Off the shelf’ new livers from stem cells, glimmer of hope

A researcher team has successfully produced a small-scale version of a human liver in the laboratory using stem cells. This could be a boon for patients waiting for liver transplants although it will take years to perfect the procedure say researchers.

31 Oct 2010

EHSI President seeks new medical technologies and investment opportunities in Poland

Emerging Healthcare Solutions President and CEO Cindy Morrissey is in Poland this week to seek out new medical technologies and investment opportunities for the company.

30 Oct 2010

Dysfunction of Grhl2 factor may affect epithelial barrier formation, contribute to congenital abnormalities

Scientists of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and the Experimental and Clinical Research Center (ECRC) of MDC and Charit- in Berlin-Buch have gained new insights into the development of epithelial cells and their molecular repertoire.

30 Oct 2010

OHSU to lead next phase of HuCNS-SC trial for NCL in children

Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC-) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

30 Oct 2010

CAN launches Highly Qualified Consumer Database about arthritis

Over 4 million Canadians suffer from arthritis, but only a tiny percentage of them are involved in influencing arthritis research in Canada. The Consumer Advisory Council (CAC) of the Canadian Arthritis Network (CAN) hopes to change that by launching a Highly Qualified Consumer (HQC) Database that will store information about Canadians willing to volunteer as consultants or collaborators to arthritis researchers.

29 Oct 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

Number of beta cells remains static after age 30: Research

Beta cells, which make insulin in the human body, do not replicate after the age of 30, indicating that clinicians may be closer to better treating diabetes.

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

New iPSC cell lines could help in treating patients with lung diseases

A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could possibly lead to new treatments for these debilitating diseases.

29 Oct 2010

Researchers develop three-dimensional culture that mimics growth patterns of colon cancer stem cells

University of Pittsburgh researchers have devised a three-dimensional system in laboratory culture that mimics the growth patterns of colon cancer stem cells in patients. Their findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Regulus receives $10M equity investment from sanofi-aventis

Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Cord Blood America enters new work agreement with Hawaii Medical Service Association

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce a new work agreement with the Hawaii Medical Service Association (HMSA), an independent licensee of the Blue Cross and Blue Shield Association, the largest and most experienced provider of health care coverage in Hawaii.

28 Oct 2010

Essential Pharmaceuticals to commence sales of cell media products acquired from Lifeblood Medical

Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell® name.

28 Oct 2010

Stem Cells News and Research

Further Reading

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

Non-dividing cells can also start cancer

‘Off the shelf’ new livers from stem cells, glimmer of hope

EHSI President seeks new medical technologies and investment opportunities in Poland

Dysfunction of Grhl2 factor may affect epithelial barrier formation, contribute to congenital abnormalities

OHSU to lead next phase of HuCNS-SC trial for NCL in children

CAN launches Highly Qualified Consumer Database about arthritis

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

Number of beta cells remains static after age 30: Research

International Congress at Spain highlights advances in neuroimmunological disease treatment

New iPSC cell lines could help in treating patients with lung diseases

Researchers develop three-dimensional culture that mimics growth patterns of colon cancer stem cells

Regulus receives $10M equity investment from sanofi-aventis

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Cord Blood America enters new work agreement with Hawaii Medical Service Association

Essential Pharmaceuticals to commence sales of cell media products acquired from Lifeblood Medical

Event guide: Supply Chain & Logistics for Cell & Gene Therapy eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo